| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | 5 | 5 | −$24.5K | Trimmed Mar 13, 26 |
| James French Hill AR02 | 1 | −$175.0K | Sold Dec 31, 25 | |
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Aug 4, 25 |
| Julia Letlow LA05 | 1 | +$8.0K | Bought Jun 17, 25 | |
| Josh Gottheimer NJ05 | 1 | −$8.0K | Sold Jun 3, 25 | |
| Rob Bresnahan PA08 | 2 | 1 | +$32.5K | Bought May 15, 25 |
| Bruce Westerman AR04 | 1 | 1 | +$0 | Sold Apr 21, 25 |
| Jefferson Shreve IN06 | 1 | 1 | +$0 | Sold Apr 11, 25 |
| Carol Devine Miller WV01 | 2 | −$40.5K | Sold Mar 10, 25 | |
| Julie Johnson TX32 | 2 | −$16.0K | Sold Feb 12, 25 | |
| Michael Rulli OH06 | 1 | −$8.0K | Sold Nov 26, 24 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Mar 13, 26 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Apr 7, 26 (25d) | |
| Feb 10, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Mar 9, 26 (27d) | |
| Dec 31, 25 | James French Hill AR02 | Self | Sell | $100,001 - $250,000 | Jan 23, 26 (23d) | |
| Dec 19, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Jan 12, 26 (24d) | |
| Nov 18, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Dec 15, 25 (27d) | |
| Aug 5, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Sep 12, 25 (38d) | |
| Aug 4, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Sep 12, 25 (39d) | |
| Jul 16, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (28d) | |
| Jun 17, 25 | Julia Letlow LA05 | Self | Buy | $1,001 - $15,000 | Jan 13, 26 (210d) | |
| Jun 3, 25 | Josh Gottheimer NJ05 | Joint | Sell | $1,001 - $15,000 | Jul 16, 25 (43d) | |
| May 30, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Jun 6, 25 (7d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Buy | $15,001 - $50,000 | May 31, 25 (16d) | |
| Apr 29, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | May 6, 25 (7d) | |
| Apr 21, 25 | Bruce Westerman AR04 | Self | Sell | $1,001 - $15,000 | May 12, 25 (21d) | |
| Apr 11, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | May 8, 25 (27d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $15,001 - $50,000 | Apr 28, 25 (20d) | |
| Mar 31, 25 | Gilbert Cisneros CA31 | Self | Sell | $15,001 - $50,000 | Apr 7, 25 (7d) | |
| Mar 10, 25 | Carol Devine Miller WV01 | Spouse | Sell | $15,001 - $50,000 | Aug 13, 26 (521d) | |
| Mar 10, 25 | Carol Devine Miller WV01 | Self | Sell | $1,001 - $15,000 | Apr 11, 25 (32d) | |
| Mar 3, 25 | Bruce Westerman AR04 | Self | Buy | $1,001 - $15,000 | Apr 16, 25 (44d) | |
| Feb 26, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Mar 6, 25 (8d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Buy | $15,001 - $50,000 | Mar 27, 25 (30d) | |
| Feb 24, 25 | Jefferson Shreve IN06 | Self | Buy | $15,001 - $50,000 | Mar 9, 25 (13d) | |
| Feb 12, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Mar 12, 25 (28d) | |
| Jan 24, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Feb 11, 25 (18d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Bourla AlbertChief Executive Officer | Purchase at price 26.34 per share. | 38K | $1.00M |
| Aug 4, 2026 | Damico Jennifer B.Officer | Sale at price 25.40 per share. | 3.3K | $83.26K |
| Aug 4, 2026 | Blaylock Ronald EDirector | Purchase at price 25.46 per share. | 39.2K | $998.82K |
| Aug 4, 2026 | Buckley Mortimer J.Director | Purchase at price 25.52 per share. | 37.6K | $960.37K |
| Jun 8, 2026 | Damico Jennifer B.Officer | Sale at price 25.70 per share. | 2K | $51.40K |
| Mar 2, 2026 | Damico Jennifer B.Officer | Stock Award(Grant) at price 0.00 per share. | 21.7K | — |
| Feb 24, 2026 | Bourla AlbertChief Executive Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 491.6K | $16.63M |
| Feb 24, 2026 | Lankler Douglas MOfficer | Conversion of Exercise of derivative security at price 33.82 per share. | 122.9K | $4.16M |
| Feb 24, 2026 | Fonseca Lidia Ph.D.Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56.9K | $1.92M |
| Feb 24, 2026 | Mcdermott MichaelOfficer | Conversion of Exercise of derivative security at price 33.82 per share. | 37.9K | $1.28M |
| Feb 24, 2026 | Damico Jennifer B.Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 17.6K | $593.81K |
| Feb 24, 2026 | Sahni PayalOfficer | Conversion of Exercise of derivative security at price 33.82 per share. | 56.9K | $1.92M |
| Feb 24, 2026 | Boshoff ChristoffelOfficer | Stock Award(Grant) at price 0.00 per share. | 13.4K | — |
| Mar 3, 2025 | Damico Jennifer B.Officer | Sale at price 25.93 per share. | 2.5K | $64.83K |
| Mar 3, 2025 | Damico Jennifer B.Officer | Stock Award(Grant) at price 0.00 per share. | 5.6K | — |
| Feb 26, 2025 | Bourla AlbertChief Executive Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 582.8K | $18.25M |
| Feb 26, 2025 | Lankler Douglas MOfficer | Conversion of Exercise of derivative security at price 31.31 per share. | 156.9K | $4.91M |
| Feb 26, 2025 | Fonseca Lidia Ph.D.Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 72.6K | $2.27M |
| Feb 26, 2025 | Susman SallyOfficer | Conversion of Exercise of derivative security at price 31.31 per share. | 85.2K | $2.67M |
| Feb 26, 2025 | Mcdermott MichaelOfficer | Conversion of Exercise of derivative security at price 31.31 per share. | 48.4K | $1.52M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.2 | 4.6 | 1.6 | -4.9 | -1.9 | -8.0 | 3.9 | 13.8 | 0.2 | -0.4 | +14.1% | ||
| 2025 | -0.0 | -0.3 | -4.1 | -3.7 | -3.8 | 3.2 | -3.9 | 6.3 | 2.9 | -3.3 | 4.4 | -3.3 | −6.1% |
| 2024 | -5.9 | -1.9 | 4.5 | -7.7 | 11.9 | -2.4 | 9.1 | -5.0 | -0.2 | -2.2 | -7.4 | 1.2 | −7.8% |
| 2023 | -13.8 | -8.1 | 0.6 | -4.7 | -2.2 | -3.5 | -1.7 | -1.9 | -6.2 | -7.9 | -0.3 | -5.5 | −43.8% |
| 2022 | -10.8 | -10.9 | 10.3 | -5.2 | 8.1 | -1.2 | -3.7 | -10.5 | -3.3 | 6.4 | 7.7 | 2.2 | −13.2% |
| 2021 | -2.5 | -6.7 | 8.2 | 6.7 | 0.2 | 1.1 | 9.3 | 7.6 | -6.6 | 1.7 | 22.8 | 9.9 | +60.4% |
| 2020 | -5.0 | -10.3 | -2.3 | 17.5 | -0.4 | -14.4 | 17.7 | -1.8 | -2.9 | -3.3 | 13.8 | -3.9 | −1.0% |
| 2019 | -2.7 | 2.1 | -2.0 | -4.4 | 2.2 | 4.3 | -10.3 | -8.5 | 1.1 | 6.8 | 0.4 | 1.7 | −10.2% |
| 2018 | 2.3 | -2.0 | -2.3 | 3.2 | -1.9 | 1.0 | 10.1 | 4.0 | 6.1 | -2.3 | 7.4 | -5.6 | +20.5% |
| 2017 | -2.3 | 7.5 | 0.3 | -0.8 | -3.7 | 2.9 | -1.3 | 2.3 | 5.2 | -1.8 | 3.4 | -0.1 | +11.5% |
| 2016 | -5.5 | -2.7 | -0.1 | 10.4 | 6.1 | 1.5 | 4.8 | -5.7 | -2.7 | -6.4 | 1.4 | 1.1 | +0.6% |
| 2015 | 0.3 | 9.8 | 1.4 | -2.5 | 2.4 | -3.5 | 7.5 | -10.6 | -2.5 | 7.7 | -3.1 | -1.5 | +3.6% |
| 2014 | -0.8 | 5.6 | 0.0 | -2.6 | -5.3 | 0.2 | -3.3 | 2.4 | 0.6 | 1.3 | 4.0 | 0.0 | +1.7% |
| 2013 | 8.8 | 0.3 | 5.4 | 0.7 | -6.3 | 2.9 | 4.4 | -3.5 | 1.8 | 6.8 | 3.4 | -3.5 | +22.1% |
| 2012 | -1.1 | -1.3 | 7.2 | 1.1 | -4.5 | 5.2 | 4.5 | -0.7 | 4.1 | 0.1 | 0.6 | 0.2 | +15.9% |
| 2011 | 4.1 | 5.6 | 5.6 | 3.2 | 2.3 | -4.0 | -6.6 | -1.4 | -6.8 | 8.9 | 4.2 | 7.8 | +23.6% |
| 2010 | 2.6 | -5.9 | -2.3 | -2.5 | -8.9 | -6.4 | 5.2 | 6.1 | 7.9 | 1.5 | -6.4 | 7.4 | −3.7% |
| 2009 | -17.7 | -15.6 | 10.6 | -1.9 | 13.7 | -1.3 | 6.2 | 4.8 | -0.9 | 2.9 | 6.7 | 0.1 | +2.7% |
| 2008 | 2.8 | -4.6 | -6.1 | -3.9 | -3.7 | -9.8 | 6.9 | 2.4 | -3.5 | -4.0 | -7.2 | 7.8 | −22.1% |
| 2007 | 1.3 | -4.9 | 1.2 | 4.8 | 3.9 | -7.0 | -8.1 | 5.7 | -1.7 | 0.7 | -3.5 | -4.3 | −12.2% |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Buy / hold / sell counts